Endocrine Abstracts

Introduction: Metastatic insulinoma is an extremely rare form of malignant insulinoma involving metastatic growth where classical surgical treatment is often impossible. Medical therapies are widely considered and reserved for those especially with inoperable insulinoma with the goals of reducing tumor size, but also of reducing hypoglycemic events either by acting directly on the insulinoma cells (reducing excess insulin secretion from the insulinoma cells or reducing tumor v...

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....